The two-day conference at Cure, 345 Park Avenue South, serves as a high-level forum for executives from Johnson & Johnson, Regeneron Pharmaceuticals, and Schrödinger to navigate the intersection of artificial intelligence, neuroscience, and MedTech. Beyond traditional main-stage presentations, the event prioritizes direct engagement through industry analyst-led Spotlight Panels and a Seed Showcase designed to provide early-stage firms with immediate investor feedback.
BioFuture 2026 Gathers Biopharma Leaders to Tackle Innovation Barriers
When scientific breakthroughs collide with shifting regulatory landscapes and volatile capital markets, the path to patient access becomes increasingly complex. BioFuture 2026, hosted by Demy-Colton, arrives in New York City this October 27–28 to bridge these gaps, uniting over 100 speakers to dissect the future of global biopharma innovation.
Sara Jane Demy, CEO of Demy-Colton, emphasizes that the industry’s greatest challenges extend beyond the laboratory. The program explicitly targets the mechanics of translation, examining how policy, regulation, and investment strategies dictate whether a discovery reaches the clinic or stalls in development. Key sessions will interrogate the sustainability of biotech funding and the ethical tensions inherent in balancing healthcare as a fundamental right against the demands of a commercial business model. The gathering concludes with a focus on AI-driven drug discovery and global market dynamics, including China’s evolving role in the biotech ecosystem.
Comments (0)
No comments yet. Be the first!